Most Clicked DiabetesPro SmartBrief Stories


1. Experts question accuracy of blood glucose meters in low glycemic range

DiabetesPro SmartBrief | Jul 24, 2015

An assessment found considerable differences in the performance of blood glucose meters in the low glycemic range, which could explain why BG measurement data is not accepted by the FDA as evidence for the efficacy of antidiabetic drugs for reducing hypoglycemia, researchers reported in Diabetes Care. They questioned whether these devices can be used in clinical trials to evaluate hypoglycemia risk. PhysiciansBriefing.com (07/22)


2. Daily soda consumption tied to increased type 2 diabetes risk

DiabetesPro SmartBrief | Jul 22, 2015

A daily serving of sugar-sweetened drinks increases type 2 diabetes risk by 13% over a decade, even after accounting for weight, according to a review in BMJ. Lead author Fumiaki Imamura said that the regular consumption of refined sugar can raise insulin resistance even in normal-weight people. HealthDay News (07/21)


3. Patients on canagliflozin experience low rates of DKA, related events

DiabetesPro SmartBrief | Jul 28, 2015

The overall incidence rates of diabetic ketoacidosis and related events were 0.07% and 0.11% among type 2 diabetes patients who were given 100 mg and 300 mg of canagliflozin, respectively, compared to 0.03% of those on a comparator. The findings in Diabetes Care were based on data from 17,596 patients with type 2 diabetes. Healio (free registration) (07/27)


4. Type 1 diabetes patients see benefit from psoriasis drug

DiabetesPro SmartBrief | Jul 23, 2015

Patients with newly diagnosed type 1 diabetes had a lower decline in C-peptide secretion over two years of follow-up after taking alefacept, a drug for psoriasis, for two 12-week courses, compared with those on placebo, according to a study in the Journal of Clinical Investigation. Researchers also found that C-peptide production didn't decline among nine of 30 patients who were evaluated for C-peptide function and the preservation of C-peptide lasted as long as 15 months after stopping treatment. PhysiciansBriefing.com (07/22)


5. Few diabetes patients meet all risk factor control targets

DiabetesPro SmartBrief | Jul 27, 2015

A study published in Diabetes Care revealed that only 35% of more than 5,000 diabetes patients evaluated met targets for A1C and LDL cholesterol levels and blood pressure, with more white than black patients meeting the targets. Researchers found 72% of patients met targets for A1C levels, 63% for LDL cholesterol levels and 73% for blood pressure. MedPage Today (free registration) (07/24)


6. Survey finds many people cannot define gluten

DiabetesPro SmartBrief | Jul 24, 2015

A survey from NSF International found 90% of people had heard about gluten sensitivity or a gluten-free diet but 54% could not correctly define the term. Some common misunderstandings about gluten are that wheat-free products are gluten-free and that all grains contain gluten. Time.com (07/21)


7. Low glucose metabolism in brain impairs memory performance

DiabetesPro SmartBrief | Jul 28, 2015

An imaging study in JAMA Neurology found that insulin resistance in individuals at high risk of developing Alzheimer's disease is tied to reduced regional cerebral glucose metabolism. Lower glucose metabolism in the left medial temporal lobe was strongly correlated with poor performance on immediate memory and delayed memory tasks, researchers found. MedPage Today (free registration) (07/27)


8. Diabetic neuropathy pain responds to inhaled cannabis, study finds

DiabetesPro SmartBrief | Jul 23, 2015

Patients with diabetic neuropathy showed improvement in pain response scores after inhaled cannabis therapy, and the reduction was dependent on dosage, researchers reported in The Journal of Pain. Researchers from the University of California at San Diego said data from the study, which compared three dosages and a placebo, showed cannabis therapy had modest effects on cognition. eMPR.com (07/20)


9. Glitazone drugs may reduce Parkinson's risk, study says

DiabetesPro SmartBrief | Jul 22, 2015

A study in PLoS Medicine found patients with diabetes who took glitazones between 1999 and 2013 had a 28% lower risk of Parkinson's disease than those who didn't take the drugs. The study also showed that patients currently taking the drugs had a 41% lower Parkinson's risk. HealthDay News (07/21)


10. Type 1 diabetes patients at increased risk for dementia, study finds

DiabetesPro SmartBrief | Jul 27, 2015

Researchers found that type 1 diabetes patients aged 60 and older were 83% more likely to develop dementia than those without the disease, according to a study presented at the Alzheimer's Association International Conference. Medscape (free registration) (07/23)




Sign up for DiabetesPro SmartBrief



Designed specifically for health care professionals, DiabetesPro SmartBrief is a FREE, daily e-mail newsletter. It provides the latest news, trends, and technology updates that matter most to health care professionals. Learn more